Table 2.
Characteristics of EC tumors in our cohort. Data on histological type, FIGO stage, tumor grade, tumor size, presence and depth of myometrial invasion, presence of lymphovascular invasion and MMR protein status were extracted from pathology reports. n indicates data availability
| Characteristics | n (%) | |
|---|---|---|
| Histological type (n = 66) | Endometrioid adenocarcinoma | 33 (50.0) |
| Endometrioid carcinoma | 26 (39.4) | |
| Serous carcinoma | 4 (6.1) | |
| Other | 3 (4.5) | |
| FIGO stage (n = 62) | I | 1 (1.6) |
| IA | 43 (69.4) | |
| IB | 10 (16.1) | |
| II | 2 (3.2) | |
| IIIC | 4 (6.5) | |
| IV | 2 (3.2) | |
| Tumor grade (n = 66) | Grade 1 | 42 (63.6) |
| Grade 2 | 15 (22.7) | |
| Grade 3 | 9 (13.6) | |
| Size (n = 62) | ≤ 2 cm | 17 (27.4) |
| > 2 cm | 45 (72.6) | |
| Myometrial invasion (n = 66) | no | 20 (30.3) |
| yes | 46 (69.7) | |
| depth reported | 40 (60.6) | |
| depth not reported | 6 (9.1) | |
| Lymphovascular invasion (n = 65) | no | 61 (93.8) |
| yes | 4 (6.2) | |
| MMR protein status (n = 60) | MMR-proficient | 46 (76.7) |
| MMR-deficient | 14 (23.3) | |
| Loss of nuclear expression | MLH1 | 9 (15.0) |
| PMS2 | 11 (18.3) | |
| MSH2 | 1 (1.7) | |
| MSH6 | 4 (6.7) |